Apo2L/TRAIL: Completed Phase Ib/II enrollment

Roche disclosed that last quarter its Genentech Inc. unit and Amgen completed enrollment of 60 patients in a Phase Ib/II trial evaluating dulanermin in combination with rituximab. Roche's Genentech un...